Literature DB >> 21422799

RET proto-oncogene mutations are restricted to codon 618 in Cypriot families with multiple endocrine neoplasia 2.

V Neocleous1, N Skordis, G Portides, E Efstathiou, C Costi, N Ioannou, M Pantzaris, V Anastasiadou, C Deltas, L A Phylactou.   

Abstract

BACKGROUND: RET germline mutations predispose to the development of inherited cancer syndrome multiple endocrine neoplasia type 2 (MEN2). Several variants of the RET proto-oncogene including G691S and S904S have been suggested to act as genetic modifiers at the age of onset ofMEN2. AIM: The aim of this study is to characterize clinically and molecularly 7 Cypriot patients with familial medullary thyroid carcinoma (FMTC) and 1 with MEN2A and also to determine the allelic frequencies of the RET variants G691S and S904S. SUBJECTS AND METHODS: Seven probands from FMTC families and 1 from MEN2A were screened for the presence of RET mutations and the G691S and S904S variants. Additionally, 226 healthy Cypriots, who served as controls were analysed in an attempt to compare the frequencies of G691S and S904S RET variants to those observed in the 8 patients.
RESULTS: The clinical diagnosis of the probands was based on clinical presentation and supported with biochemical findings. The germline C618R mutation of exon 10 was identified in all 8 probands and in 15 relatives from 7 different families. No significant difference in the G691S/S904S variants allele frequencies between patients (4/16 or 25%) and controls (124/452 or 27.4%) was found.
CONCLUSIONS: Mutational screening of the RET gene identified a common mutation (C618R) in all 8 (7 FMTC and 1 MEN2A) unrelated Cypriot patients which may be explained by a founder effect. Additionally, no association of the G691S/S904S variants was linked with the disease.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21422799     DOI: 10.3275/7605

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  56 in total

Review 1.  The phenotypes associated with ret mutations in the multiple endocrine neoplasia type 2 syndrome.

Authors:  B A Ponder
Journal:  Cancer Res       Date:  1999-04-01       Impact factor: 12.701

2.  Characterization of a multicomponent receptor for GDNF.

Authors:  J J Treanor; L Goodman; F de Sauvage; D M Stone; K T Poulsen; C D Beck; C Gray; M P Armanini; R A Pollock; F Hefti; H S Phillips; A Goddard; M W Moore; A Buj-Bello; A M Davies; N Asai; M Takahashi; R Vandlen; C E Henderson; A Rosenthal
Journal:  Nature       Date:  1996-07-04       Impact factor: 49.962

3.  Study of a kindred with pheochromocytoma, medullary thyroid carcinoma, hyperparathyroidism and Cushing's disease: multiple endocrine neoplasia, type 2.

Authors:  A L Steiner; A D Goodman; S R Powers
Journal:  Medicine (Baltimore)       Date:  1968-09       Impact factor: 1.889

Review 4.  Guidelines for diagnosis and therapy of MEN type 1 and type 2.

Authors:  M L Brandi; R F Gagel; A Angeli; J P Bilezikian; P Beck-Peccoz; C Bordi; B Conte-Devolx; A Falchetti; R G Gheri; A Libroia; C J Lips; G Lombardi; M Mannelli; F Pacini; B A Ponder; F Raue; B Skogseid; G Tamburrano; R V Thakker; N W Thompson; P Tomassetti; F Tonelli; S A Wells; S J Marx
Journal:  J Clin Endocrinol Metab       Date:  2001-12       Impact factor: 5.958

5.  Genetic analysis of RET, GFR alpha 1 and GDNF genes in Spanish families with multiple endocrine neoplasia type 2A.

Authors:  Laura Gil; Marta Azañedo; Marina Pollán; Eva Cristobal; Begoña Arribas; Luis García-Albert; Alfredo García-Sáiz; María Luisa Maestro; Antonio Torres; Javier Menárguez; José M Rojas
Journal:  Int J Cancer       Date:  2002-05-10       Impact factor: 7.396

6.  RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center.

Authors:  Rossella Elisei; Cristina Romei; Barbara Cosci; Laura Agate; Valeria Bottici; Eleonora Molinaro; Mariangela Sculli; Paolo Miccoli; Fulvio Basolo; Lucia Grasso; Furio Pacini; Aldo Pinchera
Journal:  J Clin Endocrinol Metab       Date:  2007-09-25       Impact factor: 5.958

7.  Assignment of multiple endocrine neoplasia type 2A to chromosome 10 by linkage.

Authors:  N E Simpson; K K Kidd; P J Goodfellow; H McDermid; S Myers; J R Kidd; C E Jackson; A M Duncan; L A Farrer; K Brasch
Journal:  Nature       Date:  1987 Aug 6-12       Impact factor: 49.962

8.  A single-nucleotide polymorphic variant of the RET proto-oncogene is underrepresented in sporadic Hirschsprung disease.

Authors:  P Griseri; M Sancandi; G Patrone; R Bocciardi; R Hofstra; R Ravazzolo; M Devoto; G Romeo; I Ceccherini
Journal:  Eur J Hum Genet       Date:  2000-09       Impact factor: 4.246

9.  RET polymorphisms and sporadic medullary thyroid carcinoma in a Portuguese population.

Authors:  Patrícia Costa; Rita Domingues; Luís G Sobrinho; Maria João Bugalho
Journal:  Endocrine       Date:  2005-08       Impact factor: 3.925

10.  Association of RET codon 691 polymorphism in radiation-induced human thyroid tumours with C-cell hyperplasia in peritumoural tissue.

Authors:  A Bounacer; J A Du Villard; R Wicker; B Caillou; M Schlumberger; A Sarasin; H G Suárez
Journal:  Br J Cancer       Date:  2002-06-17       Impact factor: 7.640

View more
  3 in total

1.  Distribution of RET Mutations in Multiple Endocrine Neoplasia 2 in Denmark 1994-2014: A Nationwide Study.

Authors:  Jes Sloth Mathiesen; Jens Peter Kroustrup; Peter Vestergaard; Kirstine Stochholm; Per Løgstrup Poulsen; Åse Krogh Rasmussen; Ulla Feldt-Rasmussen; Mette Gaustadnes; Torben Falck Ørntoft; Thomas van Overeem Hansen; Finn Cilius Nielsen; Kim Brixen; Christian Godballe; Anja Lisbeth Frederiksen
Journal:  Thyroid       Date:  2017-01-13       Impact factor: 6.568

2.  Total colonic aganglionosis and cleft palate in a newborn with Janus-cysteine 618 mutation of RET proto-oncogene: a case report.

Authors:  Ingrid Anne Mandy Schierz; Marcello Cimador; Mario Giuffrè; Claudia Maria Aiello; Vincenzo Antona; Giovanni Corsello; Ettore Piro
Journal:  Ital J Pediatr       Date:  2020-09-18       Impact factor: 2.638

3.  Multiple endocrine neoplasia 2 in Cyprus: evidence for a founder effect.

Authors:  P Fanis; N Skordis; S Frangos; G Christopoulos; E Spanou-Aristidou; E Andreou; P Manoli; M Mavrommatis; S Nicolaou; M Kleanthous; M A Cariolou; V Christophidou-Anastasiadou; G A Tanteles; L A Phylactou; V Neocleous
Journal:  J Endocrinol Invest       Date:  2018-02-02       Impact factor: 4.256

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.